Aurobindo Pharma has been granted a patent for a pharmaceutical composition containing pimavanserin or its salt for treating hallucinations and delusions associated with Parkinson’s disease psychosis. The patent also covers a stable pimavanserin composition in a pharmaceutically acceptable capsule, prepared through a dry blending process. GlobalData’s report on Aurobindo Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Aurobindo Pharma Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Aurobindo Pharma, nanoparticle drug conjugates was a key innovation area identified from patents. Aurobindo Pharma's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for a capsule delivering pimavanserin for parkinson's disease

Source: United States Patent and Trademark Office (USPTO). Credit: Aurobindo Pharma Ltd

A recently granted patent (Publication Number: US11648242B2) describes a pharmaceutically acceptable capsule for orally delivering pimavanserin to patients in need. The capsule contains a stable pimavanserin composition that is prepared through a dry blending process. The composition includes amorphous pimavanserin tartrate with specific particle size distribution and bulk density, along with various pharmaceutically acceptable excipients such as diluents, glidants, disintegrants, lubricants, or combinations thereof.

The patent specifies the exact formulation of the capsule, which includes 40 mg of amorphous pimavanserin tartrate, 55 mg of microcrystalline cellulose as the diluent, and 4 mg of colloidal silicon dioxide as the lubricant. Additionally, it mentions that the capsule can be either a size 3 or size 4 capsule.

Furthermore, the patent suggests an alternative formulation of the capsule that includes 1% w/w of magnesium stearate as an additional lubricant.

The patent also discloses a process for preparing the pharmaceutically acceptable capsule. The process involves blending the specified amounts of amorphous pimavanserin tartrate, microcrystalline cellulose, and colloidal silicon dioxide. The blend is then lubricated with magnesium stearate and filled into empty capsule shells.

Overall, this patent provides a detailed description of a specific capsule formulation for delivering pimavanserin orally. The formulation includes specific amounts of pimavanserin tartrate and various excipients, and the process for preparing the capsule is also outlined. This patent could be of interest to pharmaceutical companies or researchers working on the development of pimavanserin-based medications for patients in need.

To know more about GlobalData’s detailed insights on Aurobindo Pharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies